Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Cancer Approvals ImmunoOncology

ASCO 2017 Wrap-Up Podcast

Executive Summary

Analysts from Informa Pharma Intelligence's Biomedtracker, Datamonitor Healthcare and Citeline discuss their impressions following the 2017 annual meeting of the American Society of Clinical Oncology (ASCO), held in Chicago from June 2-6, 2017.

In this audio-only podcast, analysts from Informa Pharma Intelligence discuss key impressions from the 2017 annual meeting of the American Society of Clinical Oncology (ASCO). Join Robert Jeng (Biomedtracker), Dominique Fontanilla (Datamonitor Healthcare) and Maria Berezina (Citeline, Trialtrove) as they discuss topics including:

  • Anti-BCMA CAR-T therapies
  • LAG3 and GITR checkpoints
  • TRK inhibitor larotrectinib (LOXO-101)
  • Major plenary talks and drug value
  • Tumor agnostic drug approvals

Table

View full table

Related Content

Pink Sheet
Scrip
Scrip

Topics

Tags:
Cancer Approvals ImmunoOncology
Latest Headlines

Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval

Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

Sanofi Skates To Where The Puck Is With Immunology

See All
UsernamePublicRestriction

Register

SC098922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By